阿托伐他汀对慢性充血性心力衰竭患者超敏C反应蛋白和B型脑钠肽影响.docVIP

阿托伐他汀对慢性充血性心力衰竭患者超敏C反应蛋白和B型脑钠肽影响 　　【摘要】 目的 观察阿托伐他汀对慢性充血性心力衰竭患者脑钠肽（BNP）及超敏C-反应蛋白（hs-CRP）的影响。方法 慢性充血性心力衰竭患者60例随机分为用阿托伐他汀组和常规组两组， 每组30例。阿托伐他汀组在常规治疗的基础上加用阿托伐他汀10 mg/d， 疗程为12周。比较两组治疗前后血清超敏CRP和BNP水平的变化情况。结果 治疗12周后， 两组中BNP均较治疗前有显著减低（P0.05）， 且阿托伐他汀组显著低于常规组[（245.00±76.64）pg/ml VS （356.00±64.63）pg/ml（P0.05）]。常规组hs-CRP治疗后无显著下降， 但阿托伐他汀组hs-CRP较治疗前有显著下降（P0.05）， 且阿托伐他汀组与同期常规组相比差异具有统计学意义[（3.70±4.58）mg/L VS （5.36±5.06）mg/L（P0.05）]。结论 慢性充血性心力衰竭患者常规治疗基础上加用阿托伐他汀治疗可以显著减低患者hs-CRP和BNP水平， 改善心功能和预后。 　　【关键词】 阿托伐他汀；慢性充血性心力衰竭；B型脑钠肽；超敏C反应蛋白 　　Influence of atorvastatin therapy for patients with chronic congestive heart failure on B-type natriuretic peptide and high-sensitivity C-reactive protein CHEN Yan-fen， DING Yu-qin， ZHANG Lu-pin， et al. Department of Cardiology， Jurong People’s Hospital， Jurong 212400， China 　　【Abstract】 Objective To observe the effect of atorvastatin for paients with chronic congestive heart failure （CCHF） on the changes of B-type natriuretic peptide （BNP） and high-sensitivity C-reactive protein （hs-CRP）. Methods Patients with CCHF， 60 cases in all， were randomly divided into atorvastatin group and conventional group， and each group contained 30 cases. The atorvastatin group was treated with atorvastatin 10 mg/d along with routine treatment. After 12-week treatment， the changes of BNP and hs-CRP levels were detected and compared between the two groups. Results After the treatment for 12 weeks，the levels of BNP in both groups were significantly decreased， compared with those before treatment （P0.05）， and the levels of BNP in atorvastatin group were significantly lower than those in conventional group [（245.00±76.64）pg/ml VS （356.00±64.63）pg/ml （P0.05）]. The level of hs-CRP in the conventional group was not obviously changed， but the level of hs-CRP in atorvastatin group was significantly reduced， compared with those before treatment （P0.05）. Moreover， the levels of hs-CRP in atorvastatin group were lower than those in the conventional group， which had statistical sign